Peptide-Guided Missiles: Using Hormone Analogs to Deliver Chemo Directly to Tumors
Analogs of peptide hormones (LH-RH, somatostatin, bombesin) can be chemically linked to cancer drugs to deliver targeted chemotherapy to tumors, with one compound reaching phase II clinical trials.
Quick Facts
What This Study Found
Peptide hormones can be chemically attached to cancer-killing drugs (cytotoxic agents) to create targeted chemotherapy that homes in on tumors expressing specific peptide receptors. The review covers three families of peptide-drug conjugates: LH-RH analogs (AN-152, AN-207) carrying doxorubicin that target LH-RH receptors on prostate, breast, ovarian, and endometrial cancers; somatostatin analogs (AN-162, AN-238) targeting somatostatin receptors on prostate, mammary, pancreatic, colorectal, gastric, and brain cancers; and bombesin/GRP analogs (AN-215) targeting bombesin receptors.
All three approaches suppressed tumor growth and metastases in preclinical models. The LH-RH conjugate AN-152 reached clinical trials: in phase I testing in women with ovarian or endometrial cancer, it showed disease stabilization and objective tumor responses. Phase II trials were underway at the time of publication, with additional trials pending in prostate, pancreatic, and bladder cancers.
Key Numbers
3 peptide conjugate families · AN-152 (LH-RH-DOX) in phase I/II trials · Disease stabilization + objective responses in ovarian/endometrial cancer · Targets: LH-RH, somatostatin, bombesin/GRP receptors · 10+ cancer types targeted
How They Did This
Comprehensive review by the Schally group summarizing their work on cytotoxic peptide analogs for targeted cancer therapy. Covers preclinical development (in vitro and animal models) and early clinical trial results for LH-RH analog AN-152 in women with gynecological cancers. Published in Current Drug Delivery.
Why This Research Matters
This review by Nobel laureate Andrew Schally represents a pioneering approach to cancer therapy — using the body's own peptide receptor systems as homing beacons to deliver chemotherapy directly to tumors. Unlike antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs) are smaller, cheaper to produce, and can penetrate tumors more effectively. The concept laid groundwork for what has become an expanding field in targeted cancer therapy.
The Bigger Picture
Peptide-drug conjugates (PDCs) represent a parallel track to antibody-drug conjugates (ADCs), which have become blockbuster cancer drugs. PDCs have potential advantages: smaller size for better tumor penetration, lower production costs, and the ability to target peptide receptors that antibodies can't easily reach. The Schally group's work helped establish this entire field, and modern PDC research continues to build on these foundations with improved linker chemistry and more potent payloads.
What This Study Doesn't Tell Us
Review focuses primarily on the Schally group's own work, which may present a selective view. Phase I/II clinical data showed promise but the abstract doesn't report detailed efficacy numbers or long-term outcomes. Many of the compounds discussed were still in early clinical development at the time of publication (2011). The broader challenge of peptide-drug conjugate stability and pharmacokinetics is acknowledged but not fully resolved.
Questions This Raises
- ?How did AN-152 perform in the phase II trials that were underway at the time of this review?
- ?Can modern linker chemistry and payload technology improve on the first-generation peptide-drug conjugates described here?
- ?Will peptide-drug conjugates eventually compete with antibody-drug conjugates for mainstream cancer treatment?
Trust & Context
- Key Stat:
- Phase II clinical trials AN-152, a doxorubicin-conjugated LH-RH analog, showed disease stabilization and objective responses in ovarian/endometrial cancer patients and advanced to phase II testing
- Evidence Grade:
- This is an authoritative review by a Nobel Prize-winning researcher in the field. It combines extensive preclinical data with early clinical trial results. However, the clinical evidence was still in early phases at the time of publication, and the review primarily represents the authors' own research program.
- Study Age:
- Published in 2011. This is a foundational review for the peptide-drug conjugate field. While the specific compounds discussed have been further developed or superseded, the concept of peptide-targeted chemotherapy has grown into an active area of cancer drug development.
- Original Title:
- Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.
- Published In:
- Current drug delivery, 8(1), 11-25 (2011)
- Authors:
- Schally, Andrew V(41), Engel, Jorg B, Emons, Gunter, Block, Norman L, Pinski, Jacek
- Database ID:
- RPEP-01853
Evidence Hierarchy
Frequently Asked Questions
What are peptide-drug conjugates and how do they fight cancer?
Peptide-drug conjugates (PDCs) consist of a tumor-targeting peptide chemically linked to a cancer-killing drug. The peptide acts as a homing device, binding to specific receptors overexpressed on tumor cells and delivering the toxic payload directly to the cancer while minimizing damage to healthy tissue. Think of them as guided missiles at the molecular level.
Who is Andrew Schally and why is this research significant?
Andrew Schally won the Nobel Prize in Medicine in 1977 for discoveries about peptide hormone production in the brain. His group pioneered the concept of using peptide hormone analogs to target cancer therapy, developing some of the first peptide-drug conjugates to reach human clinical trials. This work laid the foundation for an entire field of targeted cancer treatment.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01853APA
Schally, Andrew V; Engel, Jorg B; Emons, Gunter; Block, Norman L; Pinski, Jacek. (2011). Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.. Current drug delivery, 8(1), 11-25.
MLA
Schally, Andrew V, et al. "Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors.." Current drug delivery, 2011.
RethinkPeptides
RethinkPeptides Research Database. "Use of analogs of peptide hormones conjugated to cytotoxic r..." RPEP-01853. Retrieved from https://rethinkpeptides.com/research/schally-2011-use-of-analogs-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.